Juno Therapeutics Inc (JUNO)

18.75
0.20 1.10
NASDAQ : Health Care
Prev Close 18.95
Open 19.11
Day Low/High 17.92 / 19.17
52 Wk Low/High 22.37 / 57.82
Volume 2.59M
Avg Volume 2.02M
Exchange NASDAQ
Shares Outstanding 105.87M
Market Cap 2.08B
EPS -2.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Juno Therapeutics Presents Data From TRANSCEND Study Showing 60% Complete Response In Patients With Relapsed Or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma

Juno Therapeutics Presents Data From TRANSCEND Study Showing 60% Complete Response In Patients With Relapsed Or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma

Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced encouraging preliminary clinical data for JCAR017 in patients...

Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out

Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out

Juno now finds itself one year, if not two years or more, behind rivals Novartis and Kite.

Juno Therapeutics Announces Complete Response And Corresponding Early Survival Data For JCAR014 In Patients With Ibrutinib-Refractory CLL

Juno Therapeutics Announces Complete Response And Corresponding Early Survival Data For JCAR014 In Patients With Ibrutinib-Refractory CLL

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced in a presentation at the 58 th American Society of Hematology...

Jim Cramer's 'Mad Money' Recap: This Rotation's Too Hard for the Bulls

Jim Cramer's 'Mad Money' Recap: This Rotation's Too Hard for the Bulls

Cramer wonders if this market has gotten too enthusiastic for the Trump agenda.

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

'We're seeing impressive, early responses with BB2121 without the toxicity,' says Bluebird CEO Nick Leschly.

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

Dow Scores Another Record as Fed Signals a Rate Hike Could Be Coming

Dow Scores Another Record as Fed Signals a Rate Hike Could Be Coming

The Dow closed higher after the minutes from the Federal Reserve's policy-setting meeting indicate that an interest rate hike could come 'relatively soon.'

Dow Clings to Record as Fed Indicates a Rate Hike Could Be Coming

Dow Clings to Record as Fed Indicates a Rate Hike Could Be Coming

The Dow remains higher after the minutes from the Federal Reserve's policy-setting meeting indicate that an interest rate hike could come 'relatively soon.'

On the Hunt for Holiday Movers

On the Hunt for Holiday Movers

I'm still bullish, but I'm looking over my shoulder to see if there are some bears sneaking up.

How to Trade Lilly, Deere and Other Most-Active Stocks Wednesday

How to Trade Lilly, Deere and Other Most-Active Stocks Wednesday

Here's a technical look on how to trade some of the most active stocks on the market today.

Dow Hits Intraday Record but Biotech Stocks Weigh on Markets

Dow Hits Intraday Record but Biotech Stocks Weigh on Markets

Stocks trade mixed Wednesday as biotech shares tumble following a sharp drop in shares of Eli Lilly.

Juno Therapeutics CAR-T Study Halts Following Additional Patient Deaths

Juno Therapeutics CAR-T Study Halts Following Additional Patient Deaths

Juno Therapeutics halted a clinical trial involving its most advanced CAR-T therapy for the second time in five months after another two cancer patients developing brain swelling.

Juno Therapeutics Places JCAR015 Phase II ROCKET Trial On Clinical Hold

Juno Therapeutics Places JCAR015 Phase II ROCKET Trial On Clinical Hold

Juno Therapeutics, Inc. (Nasdaq: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced that it has voluntarily placed on hold the Phase...

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

Hey Gilead, Stop Developing Drugs and Start Buying Biotech Companies -- Now!

For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!

Juno Therapeutics Reports Third Quarter 2016 Financial Results

Juno Therapeutics Reports Third Quarter 2016 Financial Results

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today reported financial results and business highlights for the...

Juno Therapeutics To Highlight CAR T Advances In B-cell Malignancies At ASH 2016

Juno Therapeutics To Highlight CAR T Advances In B-cell Malignancies At ASH 2016

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, today announced that seven oral and four poster presentations...

Juno Therapeutics To Report Third Quarter 2016 Financial Results On Wednesday, November 9

Juno Therapeutics To Report Third Quarter 2016 Financial Results On Wednesday, November 9

Juno Therapeutics, Inc. (NASDAQ:JUNO) will announce financial results for the third quarter 2016 on Wednesday, November 9, 2016, after the close of U.

Why Celgene Is a Core Biotech Holding

Why Celgene Is a Core Biotech Holding

Celgene's days of stellar growth will continue to stretch far into the future.

Here's a Reason Why Juno Therapeutics (JUNO) Stock Is Surging Today

Here's a Reason Why Juno Therapeutics (JUNO) Stock Is Surging Today

Juno Therapeutics (JUNO) stock was higher on Tuesday after Kite Pharma (KITE) released positive data from a lymphoma drug trial.

Kite Pharma Claims CAR-T Trial Victory, FDA Filing Next

Kite Pharma Claims CAR-T Trial Victory, FDA Filing Next

Kite Pharma's CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with an aggressive form of lymphoma, the company said Tuesday.

Has Juno Finally Beached Its Downtrend?

Has Juno Finally Beached Its Downtrend?

Juno Therapeutics' chart, and fortune, is on the rise.

The Law Offices Of Howard G. Smith Announces An Expanded Class Period In The Securities Class Action On Behalf Of Juno Therapeutics, Inc. Investors

The Law Offices Of Howard G. Smith Announces An Expanded Class Period In The Securities Class Action On Behalf Of Juno Therapeutics, Inc. Investors

Law Offices of Howard G. Smith announces that a new class action lawsuit has been filed on behalf of investors who purchased Juno Therapeutics, Inc.

JCAR014 Clinical Data Published In Science Translational Medicine: Patients With Advanced Lymphoma In Remission After T-cell Therapy

JCAR014 Clinical Data Published In Science Translational Medicine: Patients With Advanced Lymphoma In Remission After T-cell Therapy

In a paper published today in Science Translational Medicine , researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who...

September 12th Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of Deadline In The Class Action Lawsuit Against Juno Therapeutics, Inc.

September 12th Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of Deadline In The Class Action Lawsuit Against Juno Therapeutics, Inc.

Law Offices of Howard G. Smith reminds investors of the upcoming  September 12, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class") of investors who purchased...

Juno Therapeutics To Present At September 2016 Investor Conferences

Juno Therapeutics To Present At September 2016 Investor Conferences

Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced that it will webcast its presentations at two investor conferences in September.